# AMN Healthcare Services Inc: Form 10-Q for the period ended Sep 30, 2016

- Company: [AMN Healthcare Services Inc](/companies/amn.md) (CIK 1142750)
- Form: 10-Q
- Filed: 2016-11-04
- Accepted by EDGAR: Nov 4, 2016, 16:43 ET
- Period: 2016-09-30
- Accession: 0001142750-16-000024
- Inline XBRL: yes
- Main document: https://www.sec.gov/Archives/edgar/data/1142750/000114275016000024/ahs-20160930x10q.htm
- All documents and exhibits: https://www.sec.gov/Archives/edgar/data/1142750/000114275016000024/

## Figures reported in this filing

Standardized XBRL line items for the period ended 2016-09-30.

| Line item | Period | Value | XBRL concept |
| --- | --- | ---: | --- |
| Revenue | 3 months, 2016-07-01 to 2016-09-30 | $472.6m | us-gaap:Revenues |
| Revenue | 9 months, 2016-01-01 to 2016-09-30 | $1.41bn | us-gaap:Revenues |
| Cost of revenue | 3 months, 2016-07-01 to 2016-09-30 | $318.2m | us-gaap:CostOfRevenue |
| Cost of revenue | 9 months, 2016-01-01 to 2016-09-30 | $953.2m | us-gaap:CostOfRevenue |
| Gross profit | 3 months, 2016-07-01 to 2016-09-30 | $154.5m | us-gaap:GrossProfit |
| Gross profit | 9 months, 2016-01-01 to 2016-09-30 | $461.1m | us-gaap:GrossProfit |
| Selling, general and administrative | 3 months, 2016-07-01 to 2016-09-30 | $100.0m | us-gaap:SellingGeneralAndAdministrativeExpense |
| Selling, general and administrative | 9 months, 2016-01-01 to 2016-09-30 | $297.4m | us-gaap:SellingGeneralAndAdministrativeExpense |
| Operating income | 3 months, 2016-07-01 to 2016-09-30 | $46.7m | us-gaap:OperatingIncomeLoss |
| Operating income | 9 months, 2016-01-01 to 2016-09-30 | $141.9m | us-gaap:OperatingIncomeLoss |
| Interest expense | 3 months, 2016-07-01 to 2016-09-30 | $3.0m | us-gaap:InterestExpense |
| Interest expense | 9 months, 2016-01-01 to 2016-09-30 | $9.1m | us-gaap:InterestExpense |
| Income tax | 3 months, 2016-07-01 to 2016-09-30 | $16.4m | us-gaap:IncomeTaxExpenseBenefit |
| Income tax | 9 months, 2016-01-01 to 2016-09-30 | $53.3m | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months, 2016-07-01 to 2016-09-30 | $27.3m | us-gaap:NetIncomeLoss |
| Net income | 9 months, 2016-01-01 to 2016-09-30 | $79.5m | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months, 2016-07-01 to 2016-09-30 | $0.55 | us-gaap:EarningsPerShareDiluted |
| Diluted EPS | 9 months, 2016-01-01 to 2016-09-30 | $1.61 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 3 months, 2016-07-01 to 2016-09-30 | $0.57 | us-gaap:EarningsPerShareBasic |
| Basic EPS | 9 months, 2016-01-01 to 2016-09-30 | $1.66 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 3 months, 2016-07-01 to 2016-09-30 | 49,410,000 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Diluted shares (weighted) | 9 months, 2016-01-01 to 2016-09-30 | 49,287,000 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 9 months, 2016-01-01 to 2016-09-30 | $84.8m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 9 months, 2016-01-01 to 2016-09-30 | $17.7m | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Cash and equivalents | at 2016-09-30 | $15.7m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | at 2016-09-30 | $433.7m | us-gaap:AssetsCurrent |
| Total assets | at 2016-09-30 | $1.17bn | us-gaap:Assets |
| Current liabilities | at 2016-09-30 | $240.1m | us-gaap:LiabilitiesCurrent |
| Total liabilities | at 2016-09-30 | $736.6m | us-gaap:Liabilities |
| Shareholders' equity | at 2016-09-30 | $433.2m | us-gaap:StockholdersEquity |

## Management's discussion and analysis

As filed, 47,748 characters.

### of Operations

The following discussion should be read in conjunction with our consolidated financial statements and the notes thereto and other financial information included elsewhere herein and in our Annual Report on Form 10-K for the fiscal year ended December 31, 2015, filed with the Securities and Exchange Commission (“SEC”) on February 24, 2016 (“2015 Annual Report”). Certain statements in this “Management’s Discussion and Analysis of Financial Condition and Results of Operations” are “forward-looking statements.” See “Special Note Regarding Forward-Looking Statements.” We undertake no obligation to update the forward-looking statements in this Quarterly Report. References in this Quarterly Report to “AMN Healthcare,” the “Company,” “we,” “us” and “our” refer to AMN Healthcare Services, Inc. and its wholly owned subsidiaries.

### Changes to Our Reportable Segments

Effective as of January 1, 2016, we modified our reportable segments. We previously utilized three reportable segments, which we identified as follows: (1) nurse and allied healthcare staffing, (2) locum tenens staffing, and (3) physician permanent placement services. In light of our acquisitions over the past several years as well as our transition to a healthcare workforce solutions company, our management renamed our three reportable segments and also placed several of our business lines that were in our nurse and allied healthcare staffing segment into a different segment to better reflect how the business is evaluated by our chief operating decision maker. As of January 1, 2016, we began to disclose the following three reportable segments: (1) nurse and allied solutions, (2) locum tenens solutions, and (3) other workforce solutions. The nurse and allied solutions segment consists of our nurse, allied, and local staffing businesses. The locum tenens solutions segment consists of our locum tenens staffing business. The other workforce solutions segment consists of our (i) physician permanent placement services business, (ii) healthcare interim leadership staffing and executive search services business, (iii) vendor management systems business, (iv) recruitment process outsourcing business, (v) education business, (vi) medical coding and related consulting business, and (vii) workforce optimization services business. Prior period data in this “Management’s Discussion and Analysis of Financial Condition and Results of Operations” has been reclassified to conform to the new segment reporting structure.

### Overview of Our Business

We provide healthcare workforce solutions and staffing services to healthcare facilities across the nation. As an innovative workforce solutions partner, our managed services programs, or “MSP,” vendor management systems, or “VMS,” recruitment process outsourcing, or “RPO,” workforce optimization services, medical coding and consulting services, and the placement of physicians, nurses, allied healthcare professionals, and healthcare executives into temporary and permanent positions enable our clients to successfully reduce staffing complexity, increase efficiency and lead their organizations within the rapidly evolving healthcare environment. Our clients include acute and sub-acute care hospitals, community health centers and clinics, physician practice groups, retail and urgent care centers, home health facilities, and many other healthcare settings. Our clients utilize our workforce solutions and healthcare staffing services to strategically plan for and meet their workforce needs in an economically beneficial manner. Our managed services program and vendor management systems enable healthcare organizations to increase their efficiency by managing all of their supplemental workforce needs through one company or technology.

For the three months ended September 30, 2016, we recorded revenue of $472.6 million, as compared to $382.9 million for the same period last year. For the three months ended September 30, 2016, we recorded net income of $27.3 million, as compared to $33.6 million for the same period last year. For the nine months ended September 30, 2016, we recorded revenue of $1,414.4 million, as compared to $1,060.5 million for the same period last year. For the nine months ended September 30, 2016, we recorded net income of $79.5 million, as compared to $61.7 million for the same period last year.

Nurse and allied solutions segment revenue comprised 62% and 65% of total consolidated revenue for the nine months ended September 30, 2016 and 2015, respectively. Through our nurse and allied solutions segment, we provide hospitals and other healthcare facilities with a comprehensive managed services solution in which we manage and staff all of the temporary nursing and allied staffing needs of a client and traditional clinical staffing solutions of variable assignment lengths.

Locum tenens solutions revenue comprised 23% and 27% of total consolidated revenue for the nine months ended September 30, 2016 and 2015, respectively. Through our locum tenens solutions segment, we provide a comprehensive managed services solution in which we manage all of the locum tenens needs of a client and place physicians of all specialties, as well as dentists and other advanced practice providers, with clients on a temporary basis as independent contractors. These locum tenens providers are used by our healthcare facility and physician practice group clients to fill temporary vacancies created by vacation and leave schedules and to bridge the gap while they seek permanent candidates or explore expansion. Our locum tenens clients represent a diverse group of healthcare organizations throughout the United States, including hospitals, health systems, medical groups, occupational medical clinics, psychiatric facilities, government institutions, and insurance entities. The professionals we place are recruited nationwide and are typically placed on contracts with assignment lengths ranging from a few days up to one year.

Other workforce solutions segment revenue comprised 15% and 8% of total consolidated revenue for the nine months ended September 30, 2016 and 2015, respectively. Through our other workforce solutions segment, we provide hospitals and other healthcare facilities with a range of workforce solutions, including: (1) identifying and recruiting physicians for permanent placement, (2) placing interim leaders and executives across all healthcare settings, (3) a SaaS VMS through which our clients can manage all of their temporary staffing needs, (4) RPO services that leverage our expertise and support systems to replace or complement a client’s existing internal recruitment function for permanent placement needs, (5) an education program that provides custom healthcare education, research, professional practice tools, and professional development services, (6) medical coding and related consulting services, and (7) workforce optimization services that include consulting, data analytics, predictive modeling, and SaaS-based scheduling technology.

### Acquisitions During the Nine Months Ended September 30, 2016

During the nine months ended September 30, 2016, we completed three acquisitions. On January 4, 2016, we completed the acquisition of B.E. Smith (“BES”), a full-service healthcare interim leadership placement and executive search firm that places interim leaders and executives across all healthcare settings, including acute care hospitals, academic medical hospitals, children’s hospitals, physician practices, and post-acute care providers. We believe the BES acquisition will provide us additional access to healthcare executives and enhance our integrated services to hospitals, health systems, and other healthcare facilities across the nation. We include the results of BES in our other workforce solutions segment.

On January 11, 2016, we completed the acquisition of HealthSource Global Staffing (“HSG”), which provides labor disruption and rapid response staffing. We include the results of HSG in our nurse and allied solutions segment.

On June 3, 2016, we completed the acquisition of Peak Provider Solutions (“Peak”), which provides remote medical coding and consulting solutions to hospitals and physician medical groups nationwide. We include the results of Peak in our other workforce solutions segment.

For the three months ended September 30, 2016, $36.1 million of revenue relating to BES, HSG, and Peak and $4.3 million of income before income taxes relating to BES, HSG, and Peak were included in the unaudited condensed consolidated statement of operations. For the nine months ended September 30, 2016, $124.0 million of revenue relating to BES, HSG, and Peak and $20.2 million of income before income taxes relating to BES, HSG, and Peak were included in the unaudited condensed consolidated statement of operations.

### Recent Trends

The healthcare staffing market environment, including interest in workforce solutions like MSP, remains strong with demand still at near all-time highs. To address the outpacing of demand compared to supply and to meet the needs of our MSP clients, we have prioritized the fulfillment of our MSP orders. MSP revenue continues to increase faster than our traditional staffing revenue and represented approximately 50% of the nurse and allied solutions segment revenue for the nine months ended September 30, 2016. As a natural outcome of the expansion of our workforce solution offerings, we are seeing certain larger health systems representing a greater portion of our revenue as these clients purchase several different business solutions from our suite of services.

The high demand for healthcare professionals has generally allowed us to negotiate increased bill rates. In our travel nursing division, we have passed a portion of these increases on through pay rates in order to attract more nurses into our business that has put some pressure on the gross margins in the nurse and allied solutions segment. In addition, due to the prioritization of our MSP clients, we are filling more of the assignments at these clients with our own nurses and using fewer associate vendors to meet these needs. The impact of this prioritization effort in the nurse and allied solutions segment has a positive impact on revenue and gross profit, but a slightly negative effect on our gross margin percentage in light of the relatively higher gross margin percentage from our associate vendor fees.

In our locum tenens segment, demand trends remain strong in most specialties. However, the primary constraint to faster growth in the business is the ability to recruit, credential, and place an ample number of physicians to match the geographies of our demand.

The other workforce solutions segment, with its higher profitability, is positively affecting our consolidated gross and operating margins.

### Critical Accounting Policies and Estimates

The preparation of our consolidated financial statements in conformity with United States generally accepted accounting principles (“U.S. GAAP”) requires us to make estimates and judgments that affect our reported amounts of assets and liabilities, revenue and expenses, and related disclosures of contingent assets and liabilities. On an ongoing basis, we evaluate our estimates, including those related to asset impairments, accruals for self-insurance, compensation and related benefits, accounts receivable, contingencies and litigation, earn-out liabilities, and income taxes. We base these estimates on the information that is currently available to us and on various other assumptions that we believe are reasonable under the circumstances. Actual results could vary from these estimates under different assumptions or conditions. If these estimates differ significantly from actual results, our consolidated financial statements and future results of operations may be materially impacted. Our critical accounting policies and estimates remain consistent with those reported in our 2015 Annual Report.

### Results of Operations

The following table sets forth, for the periods indicated, selected unaudited condensed consolidated statements of operations data as a percentage of revenue. Our results of operations include three reportable segments: (1) nurse and allied solutions, (2) locum tenens solutions, and (3) other workforce solutions. The HSG, BES, MillicanSolutions (“Millican”), First String Healthcare (“TFS”), Onward Healthcare (“OH”), and Peak acquisitions impact the comparability of the results between the three and nine months ended September 30, 2016 and 2015 depending on the timing of the applicable acquisition. Our historical results are not necessarily indicative of our future results of operations.

*Unaudited Condensed Consolidated Statements of Operations:*

|  | Three Months Ended September 30, 2016 | 2015 | Nine Months Ended September 30, 2016 | 2015 |
| --- | ---: | ---: | ---: | ---: |
| Revenue | 100.0% | 100.0% | 100.0% | 100.0% |
| Cost of revenue | 67.3 | 67.1 | 67.4 | 68.2 |
| Gross profit | 32.7 | 32.9 | 32.6 | 31.8 |
| Selling, general and administrative | 21.2 | 21.7 | 21.0 | 21.6 |
| Depreciation and amortization | 1.6 | 1.4 | 1.5 | 1.5 |
| Income from operations | 9.9 | 9.8 | 10.1 | 8.7 |
| Interest expense, net, and other | 0.6 | 0.5 | 0.6 | 0.5 |
| Income before income taxes | 9.3 | 9.3 | 9.4 | 8.2 |
| Income tax expense | 3.5 | 0.5 | 3.8 | 2.4 |
| Net income | 5.8% | 8.8% | 5.6% | 5.8% |

### Comparison of Results for the Three Months Ended September 30, 2016 to the Three Months Ended September 30, 2015

***Revenue.*** Revenue increased 23% to $472.6 million for the three months ended September 30, 2016 from $382.9 million for the same period in 2015, due to additional revenue of approximately $43 million resulting from our HSG, BES, Millican, TFS, and Peak acquisitions with the remainder of the increase driven by 12% organic growth.

Nurse and allied solutions segment revenue increased 16% to $286.8 million for the three months ended September 30, 2016 from $246.7 million for the same period in 2015. Of the $40.1 million increase, approximately $1.8 million was attributable to the additional revenue in connection with the HSG acquisition with the remainder primarily attributable to a 12% increase in the average number of healthcare professionals on assignment and a 5% increase in the average bill rate during the three months ended September 30, 2016.

Locum tenens solutions segment revenue increased 7% to $108.6 million for the three months ended September 30, 2016 from $101.8 million for the same period in 2015. The $6.8 million increase was primarily attributable to a 1% increase in the number of days filled and a 6% increase in the revenue per day filled during the three months ended September 30, 2016.

Other workforce solutions segment revenue increased 125% to $77.3 million for the three months ended September 30, 2016 from $34.4 million for the same period in 2015. Of the $42.9 million increase, $42.0 million was attributable to the additional revenue in connection with the BES, Millican, TFS, and Peak acquisitions with the remainder primarily attributable to growth in our VMS and workforce optimization services revenue during the three months ended September 30, 2016.

***Gross Profit.*** Gross profit increased 23% to $154.5 million for the three months ended September 30, 2016 from $126.0 million for the same period in 2015, representing gross margins of 32.7% and 32.9%, respectively. The decrease in consolidated gross margin was due to higher direct costs in the nurse and allied solutions segment, partially offset by the growth of the higher margin other workforce solutions segment and higher bill-to-pay spreads in the locum tenens solutions segment during the three months ended September 30, 2016. Gross margin by reportable segment for the three months ended September 30, 2016 and 2015 was 26.7% and 27.5% for nurse and allied solutions, 31.2% and 30.7% for locum tenens solutions, and 56.7% and 78.2% for other workforce solutions, respectively. The other workforce solutions segment decrease was primarily due to the change in sales mix resulting from the additions of BES, TFS, and Peak during the three months ended September 30, 2016.

***Selling, General and Administrative Expenses.*** Selling, general and administrative (“SG&A”) expenses were $100.0 million, representing 21.2% of revenue, for the three months ended September 30, 2016, as compared to $83.1 million, representing 21.7% of revenue, for the same period in 2015. The increase in SG&A expenses was primarily due to $9.6 million of additional SG&A expenses from the HSG, BES, Millican, TFS, and Peak acquisitions, as well as increased employee headcount, variable compensation, and other expenses associated with our revenue growth. Share-based compensation expense was higher due to the higher expected share vesting amounts associated with our performance equity awards. SG&A increases as a result of acquisitions in the nurse and allied solutions and other workforce solutions segments were $0.9 million and $8.7 million, respectively. The increase in unallocated corporate overhead was primarily attributable to higher employee and variable expenses to support our growth. SG&A expenses broken down among the reportable segments, unallocated corporate overhead, and share-based compensation are as follows:

|  | (In Thousands) Three Months Ended September 30, 2016 | 2015 |
| --- | ---: | ---: |
| Nurse and allied solutions | $39,312 | $35,570 |
| Locum tenens solutions | 19,881 | 17,889 |
| Other workforce solutions | 22,985 | 13,801 |
| Unallocated corporate overhead | 15,113 | 13,817 |
| Share-based compensation | 2,704 | 2,021 |
|  | $99,995 | $83,098 |

***Depreciation and Amortization Expenses.*** Amortization expense increased 60% to $4.8 million for the three months ended September 30, 2016 from $3.0 million for the same period in 2015, primarily attributable to additional amortization expense related to the intangible assets acquired in the TFS, Millican, BES, HSG, and Peak acquisitions. Depreciation expense increased 30% to $3.0 million for the three months ended September 30, 2016 from $2.3 million for the same period in 2015, primarily attributable to fixed assets acquired as part of the TFS, Millican, BES, HSG, and Peak acquisitions and an increase in purchased and developed hardware and software placed in service for our ongoing front and back office information technology initiatives.

***Interest Expense, Net, and Other.*** Interest expense, net, and other, was $3.0 million during the three months ended September 30, 2016 as compared to $2.0 million for the same period in 2015. The increase is primarily due to a higher average debt outstanding balance for the three months ended September 30, 2016, which resulted from borrowings used primarily to finance the BES and Peak acquisitions.

***Income Tax Expense.*** Income tax expense was $16.4 million for the three months ended September 30, 2016 as compared to income tax expense of $1.9 million for the same period in 2015, reflecting effective income tax rates of 37% and 5% for the three months ended September 30, 2016 and 2015, respectively. During the three months ended September 30, 2015, we recorded a discrete federal income tax benefit of $12.2 million resulting from the IRS federal audit settlement. We currently estimate our annual effective income tax rate to be approximately 40% for 2016.

### Comparison of Results for the Nine Months Ended September 30, 2016 to the Nine Months Ended September 30, 2015

***Revenue.*** Revenue increased 33% to $1,414.4 million for the nine months ended September 30, 2016 from $1,060.5 million for the same period in 2015, due to additional revenue of approximately $148.0 million resulting from our HSG, BES, Millican, TFS, OH, and Peak acquisitions with the remainder of the increase driven by 20% organic growth.

Nurse and allied healthcare solutions segment revenue increased 27% to $877.2 million for the nine months ended September 30, 2016 from $690.2 million for the same period in 2015. Of the $187.0 million increase, $33.2 million was attributable to the additional revenue in connection with the HSG acquisition and $2.0 million was attributable to the prior year having one less week of revenue from the OH acquisition as it was consummated on January 7, 2015 (the “OH Stub Period”), with the remainder primarily attributable to a 15% increase in the average number of healthcare professionals on assignment and a 7% increase in the average bill rate during the nine months ended September 30, 2016.

Locum tenens solutions segment revenue increased 12% to $320.4 million for the nine months ended September 30, 2016 from $285.8 million for the same period in 2015. Of the $34.6 million increase, $0.6 million was attributable to the additional revenue of Locum Leaders over the OH Stub Period with the remainder primarily attributable to a 3% increase in the number of days filled and a 9% increase in the revenue per day filled during the nine months ended September 30, 2016.

Other workforce solutions segment revenue increased 157% to $216.8 million for the nine months ended September 30, 2016 from $84.4 million for the same period in 2015. Of the $132.4 million increase, $112.7 million was attributable to the additional revenue in connection with the BES, Millican, TFS, and Peak acquisitions and the additional revenue of Medefis over the OH Stub Period, with the remainder primarily attributable to an increase in billable active searches and the average placement value in the physician permanent placement business as well as growth in our VMS and workforce optimization services revenue during the nine months ended September 30, 2016.

***Gross Profit.*** Gross profit increased 37% to $461.1 million for the nine months ended September 30, 2016 from $337.6 million for the same period in 2015, representing gross margins of 32.6% and 31.8%, respectively. The increase in consolidated gross margin was due to the growth in our higher margin other workforce solutions segment and higher bill-to-pay spreads in the locum tenens solutions segment, partially offset by higher direct costs in the nurse and allied solutions segment during the nine months ended September 30, 2016. Gross margin by reportable segment for the nine months ended September 30, 2016 and 2015 was 26.7% and 27.1% for nurse and allied solutions, 31.2% and 29.8% for locum tenens solutions, and 58.6% and 77.1% for other workforce solutions, respectively. The other workforce solutions segment decrease was primarily due to the change in sales mix resulting from the additions of BES, TFS, and Peak during the nine months ended September 30, 2016.

***Selling, General and Administrative Expenses.*** SG&A expenses were $297.4 million, representing 21.0% of revenue, for the nine months ended September 30, 2016, as compared to $229.4 million, representing 21.6% of revenue, for the same period in 2015. The increase in SG&A expenses was primarily due to $28.4 million of additional SG&A expenses from the HSG, BES, Millican, TFS, and Peak acquisitions, and OH expenses over the OH Stub Period, as well as increased employee headcount, variable compensation, and other expenses associated with our revenue growth. Share-based compensation expense was higher due to the higher expected share vesting amounts associated with our performance equity awards. SG&A expense increases as a result of acquisitions in the nurse and allied solutions, locum tenens solutions and other workforce solutions segments were $3.1 million, $0.1 million and $25.2 million, respectively. The increase in the unallocated corporate overhead was primarily attributable to higher employee and variable expenses to support our growth. SG&A expenses broken down among the reportable segments, unallocated corporate overhead, and share-based compensation are as follows:

|  | (In Thousands) Nine Months Ended September 30, 2016 | 2015 |
| --- | ---: | ---: |
| Nurse and allied solutions | $115,755 | $96,437 |
| Locum tenens solutions | 56,247 | 51,030 |
| Other workforce solutions | 70,654 | 36,678 |
| Unallocated corporate overhead | 45,908 | 38,681 |
| Share-based compensation | 8,795 | 6,551 |
|  | $297,359 | $229,377 |

***Depreciation and Amortization Expenses.*** Amortization expense increased 56% to $13.6 million for the nine months ended September 30, 2016 from $8.7 million for the same period in 2015, primarily attributable to additional amortization expense related to the intangible assets acquired in the TFS, Millican, BES, HSG, and Peak acquisitions. Depreciation expense increased 20% to $8.3 million for the nine months ended September 30, 2016 from $6.9 million for the same period in 2015, primarily attributable to fixed assets acquired as part of the TFS, Millican, BES, HSG, and Peak acquisitions and an increase in purchased and developed hardware and software for our front and back office information technology initiatives.

***Interest Expense, Net, and Other.*** Interest expense, net, and other, was $9.1 million during the nine months ended September 30, 2016 and $5.8 million for the same period in 2015. The increase is primarily due to a higher average debt outstanding balance for the nine months ended September 30, 2016, which resulted from borrowings used primarily to finance the BES and Peak acquisitions.

***Income Tax Expense.*** Income tax expense was $53.3 million for the nine months ended September 30, 2016 as compared to income tax expense of $25.0 million for the same period in 2015, reflecting effective income tax rates of 40% and 29% for these periods, respectively. During the nine months ended September 30, 2015, we recorded a discrete federal income tax benefit of $12.2 million resulting from the IRS federal audit settlement. We currently estimate our annual effective income tax rate to be approximately 40% for 2016.

### Liquidity and Capital Resources

In summary, our cash flows were:

|  | (In Thousands) Nine Months Ended September 30, 2016 | 2015 |
| --- | ---: | ---: |
| Net cash provided by operating activities | $84,820 | $55,637 |
| Net cash used in investing activities | (241,271) | (105,634) |
| Net cash provided by financing activities | 162,418 | 51,290 |

Historically, our primary liquidity requirements have been for acquisitions, working capital requirements, and debt service under our credit facilities. We have funded these requirements through internally generated cash flow and funds borrowed under our credit facilities. We are an obligor under two term loans and we maintain a revolving credit facility (the “Revolver”). As of September 30, 2016, (1) the total of our term loans outstanding (including both current and long-term portions), less unamortized fees, was $202.5 million, and (2) $182.5 million was drawn with $81.6 million of available credit under the Revolver. We describe in further detail our amended credit agreement, in effect prior to the second amendment thereof, under which our term loans and Revolver are governed in “Item 8. Financial Statements and Supplementary Data—Notes to Consolidated Financial Statements—Note (8), Notes Payable and Credit Agreement” of our 2015 Annual Report. See also Note (7) of the Notes to Unaudited Consolidated Financial Statements set forth in Item 1 of this Quarterly Report.

In April 2015, we entered into an interest rate swap agreement to minimize our exposure to interest rate fluctuations on $100 million of our outstanding variable rate debt under one of our term loans for which we pay a fixed rate of 0.983% per annum and receive a variable rate equal to floating one-month LIBOR. This agreement expires on March 30, 2018, and no initial investment was made to enter into this agreement. On October 3, 2016, we reduced the interest rate swap notional amount to $40 million. See additional information in Item 1, Note (6), “Derivative Instruments.”

We believe that cash generated from operations and available borrowings under the Revolver will be sufficient to fund our operations for the next 12 months and beyond. We intend to finance potential future acquisitions either with cash provided from operations, borrowings under the Revolver, bank loans, debt or equity offerings, or some combination of the foregoing. The following discussion provides further details of our liquidity and capital resources.

### Operating Activities

Net cash provided by operating activities for the nine months ended September 30, 2016 was $84.8 million, compared to $55.6 million for the same period in 2015. The increase in net cash provided by operating activities was primarily attributable to (1) improved operating results, (2) a decrease in restricted cash, cash equivalents and investments attributable to cash payments made to our captive insurance entity, which are restricted for use by the captive for future claim payments and, to a lesser extent, its working capital needs, and (3) a decrease in accounts receivable and subcontractor receivable between periods due to timing of collections. The overall increase was partially offset by a decrease in accounts payable and accrued expenses as well as accrued compensation and benefits between periods due to timing of payments. Our Days Sales Outstanding (“DSO”) was 64 days at each of September 30, 2016 and December 31, 2015, and 60 days at September 30, 2015.

### Investing Activities

Net cash used in investing activities for the nine months ended September 30, 2016 was $241.3 million, compared to $105.6 million for the same period in 2015. The increase was primarily due to $216.6 million used for the acquisitions of BES and HSG in January 2016 and Peak in June 2016 as compared to $81.1 million used for acquisitions during the nine months ended September 30, 2015. Capital expenditures were $17.7 million and $21.1 million for the nine months ended September 30, 2016 and 2015, respectively.

### Financing Activities

Net cash provided by financing activities during the nine months ended September 30, 2016 was $162.4 million, primarily due to proceeds received of $124.0 million from the Revolver and $75.0 million from a new term loan under our amended credit agreement, which we used to fund our BES and Peak acquisitions, partially offset by (1) the repayments of $8.4 million under our term loans and $24.0 million under the Revolver, and (2) $5.6 million cash paid for shares withheld for payroll taxes resulting from the vesting of employee equity awards. Net cash provided by financing activities during the nine months ended September 30, 2015 was $51.3 million, primarily due to accessing $84.5 million under the Revolver to finance the OH acquisition, partially offset by (1) $32.6 million for repayments of debt, including both regularly scheduled payments and paying off our prior credit facilities, and (2) $11.5 million in cash paid for shares withheld for payroll taxes resulting from the vesting of employee equity awards.

### Letters of Credit

At September 30, 2016, we maintained outstanding standby letters of credit totaling $16.6 million as collateral in relation to our professional liability insurance agreements, workers’ compensation insurance agreements, and a corporate office lease agreement. Of the $16.6 million of outstanding letters of credit, we have collateralized $5.6 million in cash and cash equivalents and the remaining amounts are collateralized by the Revolver. Outstanding standby letters of credit at December 31, 2015 totaled $15.8 million.

### 5.125% Senior Notes Due 2024

On October 3, 2016, AMN Healthcare, Inc. (the “Issuer”), a wholly owned subsidiary of AMN Healthcare Services, Inc. (the “Parent”), completed the issuance of $325.0 million aggregate principal amount of 5.125% Senior Notes due 2024 (the “Notes”). The Notes will mature on October 1, 2024. Interest on the Notes is payable semi-annually in arrears on April 1 and October 1 of each year, commencing April 1, 2017.

The Notes were issued pursuant to an Indenture (the “Indenture”), dated as of October 3, 2016, by and among the Issuer, the Parent, the subsidiary guarantors party thereto (collectively, together with the Parent, the “Guarantors”) and U.S. Bank National Association, as trustee, and are senior unsecured obligations of the Issuer. The Guarantors have guaranteed (the “Guarantees”) the Issuer’s obligations under the Notes and the Indenture on a senior unsecured basis. The Guarantors include the Parent and the subsidiaries of the Issuer that guarantee the Issuer’s credit facilities under the amended credit agreement.

The Notes will rank *pari passu* in right of payment with all of the Issuer’s existing and future senior indebtedness, senior to all of the Issuer’s existing and future subordinated indebtedness and effectively subordinated to all of the Issuer’s existing and future secured indebtedness, to the extent of the value of the collateral securing such indebtedness.

The Guarantees will be each Guarantor’s senior unsecured obligations and will rank *pari passu* in right of payment with all of such Guarantor’s existing and future senior indebtedness, senior to all of such Guarantor’s existing and future subordinated indebtedness and effectively subordinated to all of such Guarantor’s existing and future secured indebtedness, to the extent of the value of the collateral securing such indebtedness.

The Notes and the Guarantees will be structurally subordinated to all existing and future indebtedness and other liabilities and preferred stock of any of the Issuer’s subsidiaries that do not guarantee the Notes.

At any time and from time to time on and after October 1, 2019, the Issuer will be entitled at its option to redeem all or a portion of the Notes upon not less than 30 nor more than 60 days’ notice, at the redemption prices (expressed in percentages of principal amount on the redemption date) set forth below, plus accrued and unpaid interest, if any, to (but excluding) the redemption date (subject to the right of holders of record of the Notes on the relevant record date to receive interest due on the relevant interest payment date), if redeemed during the twelve month period commencing on October 1 of the years set forth below:

| Period | Redemption Price |
| --- | ---: |
| 2019 | 103.844% |
| 2020 | 102.563% |
| 2021 | 101.281% |
| 2022 and thereafter | 100% |

At any time and from time to time prior to October 1, 2019, the Issuer may also redeem Notes with the net cash proceeds of certain equity offerings in an aggregate principal amount not to exceed 40% of the aggregate principal amount of the Notes issued, at a redemption price (expressed as a percentage of principal amount) of 105.125% of the principal amount thereof plus accrued and unpaid interest to (but excluding) the applicable redemption date.

In addition, the Issuer may redeem some or all of the Notes at any time and from time to time prior to October 1, 2019 at a redemption price equal to 100% of the principal amount of the Notes redeemed, plus accrued and unpaid interest thereon, if any, to (but excluding) the applicable redemption date, plus a “make-whole” premium based on the applicable treasury rate plus 50 basis points.

Upon the occurrence of specified change of control events as defined in the Indenture, the Issuer must offer to repurchase the Notes at 101% of the principal amount, plus accrued and unpaid interest, if any, to (but excluding) the purchase date.

The Indenture contains covenants that, among other things, restrict the ability of the Parent, the Issuer and their restricted subsidiaries to:

- sell assets,
- pay dividends or make other distributions on capital stock or make payments in respect of subordinated indebtedness,
- make investments,
- incur additional indebtedness or issue preferred stock,
- create certain liens,
- enter into agreements that restrict dividends or other payments from their restricted subsidiaries to the Issuer, the Parent or their restricted subsidiaries,
- consolidate, merge or transfer all or substantially all of their assets,
- engage in transactions with affiliates, and
- create unrestricted subsidiaries.

These covenants are subject to a number of important exceptions and qualifications. The Indenture contains affirmative covenants and events of default that are customary for Indentures governing high yield securities. The Notes and the Guarantees are not subject to any registration rights agreement.

We used the proceeds from the issuance of the Notes to (1) repay $131.3 million of our existing Term Loan indebtedness, (2) repay $7.2 million of our existing Additional Term Loan indebtedness, (3) repay $182.5 million under the Revolver, and (4) pay fees and expenses related to the offering and sale of the Notes.

### Off-Balance Sheet Arrangements

At September 30, 2016, we did not have any off-balance sheet arrangement that has or is reasonably likely to have a current or future effect on our financial condition, changes in financial condition, revenues or expenses, results of operations, liquidity, capital expenditures, or capital resources that is material to investors.

### Contractual Obligations

There have been no material changes to the table entitled “Contractual Obligations” in Part II, Item 7, “Management’s Discussion and Analysis of Financial Condition and Results of Operations” set forth in our 2015 Annual Report that occurred during the nine months ended September 30, 2016, other than an increase of $39 million in the amount outstanding under the Revolver.

### Recent Accounting Pronouncements

In May 2014, the Financial Accounting Standards Board (“FASB”) issued new accounting guidance related to revenue recognition. This new standard will replace all current U.S. GAAP guidance on this topic and eliminate all industry-specific guidance. The new revenue recognition standard provides a unified model to determine when and how revenue is recognized. The core principle is that a company should recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration for which the entity expects to be entitled in exchange for those goods or services. This guidance provides that the standard will be effective for us beginning January 1, 2017 and can be applied either retrospectively to each period presented or as a cumulative-effect adjustment as of the date of adoption. In July 2015, the FASB voted to amend the guidance by approving a one-year delay in the effective date of the new standard to 2018. Under this deferred implementation, early adoption is allowed, but not earlier than the original effective date. We are currently evaluating the timing of this new standard’s adoption and the effect that adopting it will have on our financial statements and related disclosures.

In February 2016, the FASB issued ASU 2016-02, “Leases.” This standard requires organizations that lease assets to recognize the assets and liabilities created by those leases. The standard also will require disclosures to help investors and other financial statement users better understand the amount, timing, and uncertainty of cash flows arising from leases. The ASU becomes effective for public companies for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2018. We are currently evaluating the timing of this new standard’s adoption and the effect that adopting it will have on our financial statements and related disclosures.

In March 2016, the FASB issued ASU 2016-08, “Revenue from Contracts with Customers - Principal versus Agent Consideration (Reporting Revenue Gross versus Net).” The standard attempts to clarify the implementation guidance on principal versus agent considerations. When an entity that is a principal satisfies a performance obligation, the entity recognizes revenue in the gross amount of consideration to which it expects to be entitled in exchange for the specified good or service transferred to the customer. When an entity that is an agent satisfies a performance obligation, the entity recognizes revenue in the amount of any fee or commission to which it expects to be entitled in exchange for arranging for the specified good or service to be provided by the other party. The ASU affects the guidance in ASU 2014-09, Revenue from Contracts with Customers (Topic 606), which is not yet effective. The effective date and transition requirements for the amendments in this ASU are the same as the effective date and transition requirements of ASU 2014-09. ASU No. 2015-14, Revenue from Contracts with Customers (Topic 606): Deferral of the Effective Date, defers the effective date of ASU 2014-09 by one year to annual periods beginning after December 15, 2017. We are currently evaluating the timing of this new standard’s adoption and the effect that adopting it will have on our financial statements and related disclosures.

In March 2016, the FASB issued ASU 2016-09, “Stock Compensation - Improvements to Employee Share-Based Payment Accounting.” The guidance attempts to simplify the accounting for share-based payment transactions in several areas, including the following: income tax consequences, classification of awards as either equity or liabilities, forfeitures, expected term, and statement of cash flows classification. For public entities, ASU 2016-09 is effective for fiscal years beginning after December 15, 2016, and interim periods within those annual periods. We are currently evaluating the timing of this new standard’s adoption. The income tax benefit impact for the nine months ended September 30, 2016, if the standard had been adopted, would have been $2.8 million.

In August 2016, the FASB issued ASU 2016-15, “Statement of Cash Flows (Topic 230): Classification of Certain Cash Receipts and Cash Payments.” The standard provides guidance on how certain cash receipts and payments are presented and classified in the statement of cash flows. For public entities, ASU 2016-15 is effective for fiscal years beginning after December 15, 2017, and interim periods within those annual periods, and requires a retrospective approach. Early ad option is permitted, including adoption in an interim period. We are currently evaluating the timing of this new standard’s adoption and the effect that adopting it will have on our financial statements and related disclosures.

There have been no other new accounting pronouncements issued but not yet adopted that are expected to materially affect our consolidated financial condition or results of operations.

### Special Note Regarding Forward-Looking Statements

This Quarterly Report contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. We base these forward-looking statements on our expectations, estimates, forecasts, and projections about future events and about the industry in which we operate. Forward-looking statements are identified by words such as “believe,” “anticipate,” “expect,” “intend,” “plan,” “will,” “should,” “would,” “project,” “may,” variations of such words, and other similar expressions. In addition, any statements that refer to projections of financial items, anticipated growth, future growth and revenues, future economic conditions and performance, plans, objectives and strategies for future operations, expectations, or other characterizations of future events or circumstances are forward-looking statements. All forward-looking statements involve risks and uncertainties. Our actual results could differ materially from those discussed in, or implied by, these forward-looking statements. Factors that could cause actual results to differ materially from those implied by the forward-looking statements in this Quarterly Report are set forth in our 2015 Annual Report and include but are not limited to:

- the effects of economic downturns or slow recoveries, which could result in less demand for our services and pricing pressures;
- the negative effects that intermediary organizations may have on our ability to secure new and profitable contracts with our clients;
- the level of consolidation and concentration of buyers of healthcare workforce solutions and staffing services, which could affect the pricing of our services and our ability to mitigate concentration risk;
- any inability on our part to quickly respond to changing marketplace conditions, such as alternative modes of healthcare delivery, reimbursement, or client needs;
- the ability of our clients to retain and increase the productivity of their permanent staff, or their ability to increase the efficiency and effectiveness of their internal recruiting efforts, through online recruiting or otherwise, which may negatively affect our revenue, results of operation, and cash flow;
- any inability on our part to grow and operate our business profitably in compliance with federal and state healthcare industry regulation, including conduct of operations, costs and payment for services and payment for referrals as well as laws regarding employment practices and government contracting;
- any challenge to the classification of certain of our healthcare professionals as independent contractors, which could adversely affect our profitability;
- the effect of investigations, claims, and legal proceedings alleging medical malpractice, violation of employment and wage regulations and other legal theories of liability asserted against us, which could subject us to substantial liabilities;
- security breaches and other disruptions that could compromise our information, which could cause our business and reputation to suffer and could subject us to substantial liabilities;
- any inability on our part to implement new infrastructure and technology systems effectively or technology disruptions, either of which may adversely affect our operating results and our ability to manage our business effectively;
- disruption to or failure of our software-as-a-service (SaaS)-based technology within certain of our service offerings or our inability to adequately protect our intellectual property rights with respect to such technology, which could reduce client satisfaction, harm our reputation, and negatively affect our business;
- our dependence on third parties for the execution of certain critical functions;
- cybersecurity risks and cyber incidents, which could adversely affect our business or disrupt our operations;
- any inability on our part to recruit and retain sufficient quality healthcare professionals at reasonable costs;
- any inability on our part to properly screen and match quality healthcare professionals with suitable placements;
- any inability on our part to successfully attract and retain a sufficient number of quality sales and operations personnel;
- the loss of our key officers and management personnel, which could adversely affect our business and operating results;
- any inability on our part to maintain our positive brand awareness and identity;
- any inability on our part to consummate and effectively incorporate acquisitions into our business operations;
- any recognition by us of an impairment to goodwill or indefinite-lived intangibles;
- the effect of significant adverse adjustments by us to our insurance-related accruals, which could decrease our earnings or increase our losses, as the case may be; and
- our level of indebtedness and any inability on our part to generate sufficient cash flow to service our debt.

## Market risk

As filed, 1,450 characters.

Market risk is the risk of loss arising from adverse changes in market rates and prices, such as interest rates, foreign currency exchange rates, and commodity prices. During the three and nine months ended September 30, 2016, our primary exposure to market risk was interest rate risk associated with our variable interest debt instruments. In April 2015, we entered into an interest rate swap agreement to minimize our exposure to interest rate fluctuations on $100 million of our outstanding variable rate debt under one of our term loans for which we pay a fixed rate of 0.983% per annum and receive a variable rate equal to floating one-month LIBOR. This agreement expires on March 30, 2018, and no initial investment was made to enter into it. A 100 basis point increase in interest rates on our variable rate debt would not have resulted in a material effect on our unaudited condensed consolidated financial statements for the three and nine months ended September 30, 2016. On October 3, 2016, we completed the issuance of $325.0 million aggregate principal amount of the Notes. With the proceeds from the issuance of the Notes, we repaid the full existing balance under the Revolver and a portion of the outstanding balance under the term loan indebtedness. During the three and nine months ended September 30, 2016, we generated all of our revenue in the United States. Accordingly, we believe that our foreign currency risk is immaterial.

## Controls and procedures

As filed, 1,207 characters.

We carried out an evaluation, under the supervision and with the participation of our management, including our Chief Executive Officer and Chief Financial Officer, of the effectiveness of our disclosure controls and procedures, as defined in Rules 13a-15(e) and 15d-15(e) of the Securities Exchange Act of 1934. Based on that evaluation, our Chief Executive Officer and Chief Financial Officer have concluded that our disclosure controls and procedures as of September 30, 2016 were effective to ensure that information required to be disclosed by us in reports that we file or submit under the Securities Exchange Act of 1934 is recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms, and that such information is accumulated and communicated to management, including our Chief Executive Officer and Chief Financial Officer, as appropriate, to allow timely decisions regarding required disclosure.

There were no changes in our internal control over financial reporting that occurred during the quarter ended September 30, 2016 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

## Risk factors

As filed, 135 characters.

We do not believe that there have been any material changes to the risk factors disclosed in Part I, Item 1A of our 2015 Annual Report.

Filed Nov 4, 2016.
Source: SEC EDGAR, the filing index for accession 0001142750-16-000024. Last ingested by Listed: Nov 5, 2026, 17:59 ET. No prices; not investment advice.
